Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a partnership to tackle ...

However, Boston-based biotech Decibel Therapeutics is bringing a thorough understanding of the molecular and cell biology of the inner ear to develop a pipeline of potentially transformative gene ...